French drugmaker Sanofi has agreed to acquire US-based vaccines company Dynavax Technologies in an all-cash deal valued at $2.2 billion (€1.9 billion), expanding its vaccine portfolio as it looks to diversify growth beyond its asthma drug Dupixent.
